Therapeutic agents for treating restless leg syndrome
US11660279B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2019 |
| Grant date | May 30, 2023 |
| Priority date | — |
| Expiry date | Sep 2, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides for treatments of restless legs syndrome (RLS) or one or more symptoms associated with RLS comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.